Sign up to save your podcasts
Or
Share Second-Line Solutions in Metastatic TNBC: ADC Selection, Sequencing, and Safety
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Second-Line Solutions in Metastatic TNBC: ADC Selection, Sequencing, and Safety
CME credits: 0.25
Valid until: 25-03-2026
Claim your CME credit at https://reachmd.com/programs/cme/second-line-solutions-in-metastatic-tnbc-adc-selection-sequencing-and-safety/32680/
When choosing an antibody-drug conjugate (ADC) for the second-line treatment of triple-negative breast cancer (TNBC), efficacy, sequencing, and management of toxicities are key. Do you know how best to choose a therapy for your patients? Our experts have the answers and strategies you need!
=
View all episodes
By ReachMD
4.3
33 ratings
CME credits: 0.25
Valid until: 25-03-2026
Claim your CME credit at https://reachmd.com/programs/cme/second-line-solutions-in-metastatic-tnbc-adc-selection-sequencing-and-safety/32680/
When choosing an antibody-drug conjugate (ADC) for the second-line treatment of triple-negative breast cancer (TNBC), efficacy, sequencing, and management of toxicities are key. Do you know how best to choose a therapy for your patients? Our experts have the answers and strategies you need!
=